• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Biodesix Inc.

    5/20/25 4:11:48 PM ET
    $BDSX
    Medical Specialities
    Health Care
    Get the next $BDSX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)


    BIODESIX INC

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    09075X108

    (CUSIP Number)


    Jack W. Schuler
    100 Tri-State International, Suite 125
    Lincolnshire, IL, 60069
    (224) 880-1210

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    05/16/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    09075X108


    1 Name of reporting person

    SCHULER JACK W
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    414,811.00
    8Shared Voting Power

    35,918,174.00
    9Sole Dispositive Power

    414,811.00
    10Shared Dispositive Power

    35,918,174.00
    11Aggregate amount beneficially owned by each reporting person

    36,332,985.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    24.7 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    (1) Sole voting and dispositive power includes 414,811 Shares (as defined herein) that the Reporting Person has the right to acquire within 60 days of the date of this filing. (2) Percent of class is calculated based on a total of 146,563,031 Shares outstanding as of May 7, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC (as defined herein) on May 13, 2025, plus 414,811 Shares that the Reporting Person has the right to acquire within 60 days of the date of this filing.


    SCHEDULE 13D

    CUSIP No.
    09075X108


    1 Name of reporting person

    Jack W. Schuler Living Trust
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    ILLINOIS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    20,918,174.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    20,918,174.00
    11Aggregate amount beneficially owned by each reporting person

    20,918,174.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.3 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    (1) Percent of class is calculated based on a total of 146,563,031 Shares outstanding as of May 7, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on May 13, 2025.


    SCHEDULE 13D

    CUSIP No.
    09075X108


    1 Name of reporting person

    Jack W. Schuler 2025 GRAT
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    ILLINOIS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,000,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,000,000.00
    11Aggregate amount beneficially owned by each reporting person

    15,000,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    10.2 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    (1) Percent of class is calculated based on a total of 146,563,031 Shares outstanding as of May 7, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on May 13, 2025.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.001 per share
    (b)Name of Issuer:

    BIODESIX INC
    (c)Address of Issuer's Principal Executive Offices:

    919 WEST DILLON RD, LOUISVILLE, COLORADO , 80027.
    Item 1 Comment:
    This Amendment No. 7 to Schedule 13D ("Amendment No. 7") is being filed by the undersigned, pursuant to section 240.13d-2(a), to amend and supplement the Schedule 13D filed with the U.S. Securities and Exchange Commission (the "SEC") on November 9, 2020 (the "Initial Schedule 13D"), as amended on January 28, 2022, on April 11, 2022, on November 23, 2022, on August 11, 2023, on April 9, 2024, and on May 23, 2024 (collectively, the "Schedule 13D"), with respect to the common stock, par value $0.001 per share (the "Shares"), of Biodesix, Inc. (the "Issuer" or the "Company"), whose principal executive offices are located at 919 West Dillon Rd., Louisville, Colorado 80027.
    Item 2.Identity and Background
    (a)
    Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows: This Schedule 13D is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): i. Jack W. Schuler ("Mr. Schuler"); ii. Jack W. Schuler Living Trust (the "Trust"); and iii. Jack W. Schuler 2025 GRAT (the "GRAT").
    (b)
    The principal address of each of the Reporting Persons is 100 Tri-State International, Suite 125, Lincolnshire, Illinois 60069.
    (c)
    Mr. Schuler is principally engaged in the business of investing in securities. The Trust is a living trust established by Mr. Schuler. Mr. Schuler serves as sole trustee of the Trust. The GRAT is a grantor retained annuity trust established by Mr. Schuler. Mr. Schuler serves as sole trustee of the GRAT.
    (d)
    None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Mr. Schuler is a United States citizen. Each of the Trust and the GRAT is organized under the laws of the State of Illinois.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 of the Schedule 13D is hereby amended and supplemented as follows: On January 29, 2025, 15,000,000 Shares previously held by the Trust were transferred to the GRAT for no additional consideration. On May 16, 2025, Mr. Schuler, through the Trust, purchased 4,000,000 Shares in the open market, through a broker, in multiple transactions at prices ranging from $0.2215 to $0.3397, inclusive, with a weighted average price of $0.2675 per Share. On May 19, 2025, Mr. Schuler, through the Trust, purchased 723,239 Shares in the open market, through a broker, in multiple transactions at prices ranging from $0.2997 to $0.36, inclusive, with a weighted average price of $0.341 per Share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth herein. The source of funds for the purchases reported herein was Mr. Schuler's personal funds.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5(a)-(c) of the Schedule 13D is hereby amended and restated as follows: As of the date hereof, Mr. Schuler may be deemed to beneficially own, in the aggregate, 36,332,985 Shares, which represents approximately 24.7% of the Shares outstanding. Mr. Schuler's beneficial ownership consists of (i) 83,152 Shares that Mr. Schuler has the right to acquire upon exercise of options exercisable within 60 days of the date of this filing, (ii) 331,659 Shares that Mr. Schuler has the right to acquire upon settlement of vested RSUs within 60 days of the date of this filing, (iii) 20,918,174 Shares held by the Trust, representing approximately 14.3% of the Shares outstanding, and (iv) 15,000,000 Shares held by the GRAT, representing approximately 10.2% of the Shares outstanding The foregoing beneficial ownership percentages are based on a total of (i) 146,563,031 Shares outstanding as of May 7, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on May 13, 2025, and, for purposes of calculating Mr. Schuler's beneficial ownership percentage, (ii) 414,811 Shares that Mr. Schuler has the right to acquire within 60 days of the date of this filing.
    (b)
    Mr. Schuler has the sole power to vote or direct the vote, and the sole power to dispose or direct the disposition of, the 414,811 Shares that Mr. Schuler has the right to acquire within 60 days of the date of this filing. As sole trustee of the Trust, Mr. Schuler shares with the Trust the power to vote or direct the vote, and the power to dispose or direct the disposition of, the 20,918,174 Shares beneficially owned by the Trust. As sole trustee of the GRAT, Mr. Schuler shares with the GRAT the power to vote or direct the vote, and the power to dispose or direct the disposition of, the 15,000,000 Shares beneficially owned by the GRAT.
    (c)
    The response to Item 3 of this Amendment No. 7 is incorporated by reference herein. Except as set forth in this Amendment No. 7, no transactions in the Shares have been effected by the Reporting Persons within the past 60 days.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 7 Joint Filing Agreement, dated as of May 20, 2025, by and among Jack W. Schuler, Jack W. Schuler Living Trust and Jack W. Schuler 2025 GRAT

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    SCHULER JACK W
     
    Signature:/s/ Jack W. Schuler
    Name/Title:Jack W. Schuler
    Date:05/20/2025
     
    Jack W. Schuler Living Trust
     
    Signature:/s/ Jack W. Schuler
    Name/Title:Jack W. Schuler, Trustee
    Date:05/20/2025
     
    Jack W. Schuler 2025 GRAT
     
    Signature:/s/ Jack W. Schuler
    Name/Title:Jack W. Schuler, Trustee
    Date:05/20/2025
    Get the next $BDSX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDSX

    DatePrice TargetRatingAnalyst
    5/14/2025Outperform → Mkt Perform
    William Blair
    9/16/2024Sector Outperform
    Scotiabank
    7/26/2024$3.00Buy
    Craig Hallum
    5/13/2024$2.80Buy
    TD Cowen
    5/3/2024$3.00Buy
    Lake Street
    11/17/2021$21.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO, Sec'y & Treasurer Cowie Robin Harper converted options into 3,157 shares and sold $411 worth of shares (988 units at $0.42), increasing direct ownership by 0.87% to 250,794 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    8/14/25 5:25:14 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Development Officer Pestano Gary Anthony converted options into 1,379 shares and sold $184 worth of shares (442 units at $0.42), increasing direct ownership by 0.60% to 157,878 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    8/14/25 5:24:35 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Commercial Officer O'Kane Kieran converted options into 1,489 shares and sold $198 worth of shares (476 units at $0.42), increasing direct ownership by 0.73% to 140,065 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    8/14/25 5:24:51 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biodesix downgraded by William Blair

    William Blair downgraded Biodesix from Outperform to Mkt Perform

    5/14/25 8:54:25 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Scotiabank initiated coverage on Biodesix

    Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform

    9/16/24 8:45:16 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on Biodesix with a new price target

    Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00

    7/26/24 7:48:11 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics

    LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher's collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix Development Services offerings, including customizable options that enable the world's leading life sciences companies, biopharmaceutical, and medical research institutions with scientific, technological, and operational capabilities. As Thermo Fisher announced in July 2025, Biodesix was an instrumental partner in the vali

    8/19/25 9:47:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Second Quarter 2025 Results and Highlights

    Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2025. "We had strong second quarter performance with 12% revenue growth and 80% gross margins," said Scott Hutton, Chief Executive Officer. "Last quarter, we expanded our commercial

    8/7/25 4:06:26 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

    BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. Canaccord Genuity 45th Annual Growth Conference Fireside Chat Date: Tuesday, August 12, 2025Fireside Chat Time: 4:30 PM ETLocation: Boston, MA The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at biodesix.com. About Biodesix Biodesix is

    8/5/25 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schuler Jack W bought $1,316,624 worth of shares (4,723,239 units at $0.28) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    5/20/25 4:11:31 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Schuler Jack W bought $122,840 worth of shares (100,000 units at $1.23) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    11/22/24 12:30:34 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Kennedy Lawrence T. Jr bought $40,562 worth of shares (35,000 units at $1.16) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    11/22/24 12:30:13 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    SEC Filings

    View All

    SEC Form 10-Q filed by Biodesix Inc.

    10-Q - BIODESIX INC (0001439725) (Filer)

    8/7/25 4:11:36 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIODESIX INC (0001439725) (Filer)

    8/7/25 4:05:32 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form S-8 filed by Biodesix Inc.

    S-8 - BIODESIX INC (0001439725) (Filer)

    5/30/25 4:10:49 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodesix Inc.

    SC 13G/A - BIODESIX INC (0001439725) (Subject)

    11/13/24 7:30:22 AM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Biodesix Inc.

    SC 13G - BIODESIX INC (0001439725) (Subject)

    6/24/24 12:16:38 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Biodesix Inc. (Amendment)

    SC 13D/A - BIODESIX INC (0001439725) (Subject)

    5/23/24 7:10:37 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Financials

    Live finance-specific insights

    View All

    Biodesix Announces Second Quarter 2025 Results and Highlights

    Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2025. "We had strong second quarter performance with 12% revenue growth and 80% gross margins," said Scott Hutton, Chief Executive Officer. "Last quarter, we expanded our commercial

    8/7/25 4:06:26 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025

    LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on Thursday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after t

    7/24/25 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces First Quarter 2025 Results and Highlights

    Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025. "Our quarter was highlighted by continued progress toward our three key goals for 2025 – growing top line revenue, improving operational efficiencies and leverage, and advancing our pipeline," said Sc

    5/13/25 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Leadership Updates

    Live Leadership Updates

    View All

    Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo

    12/16/22 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a

    12/8/21 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care